{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:49:08Z","timestamp":1790642948422,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The anti\u2013B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed\/refractory multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions\/6-week cycles). Patients had progression after \u2265 2 lines of prior therapy and no extramedullary disease. Minimal residual disease (MRD) response was defined as &lt; 1 tumor cell\/10\n                      <jats:sup>4<\/jats:sup>\n                      bone marrow cells by flow cytometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Forty-two patients received AMG 420 at 0.2-800 \u03bcg\/d. Median age was 65 years, and median disease duration was 5.2 years. Median exposure was 1 cycle (range, 1-10 cycles) and 7 cycles (range, 1-10 cycles) for responders. Patients discontinued for disease progression (n = 25), adverse events (AEs; n = 7), death (n = 4), completion of 10 cycles (n = 3), and consent withdrawal (n = 1). Two patients remain on treatment. There were 2 nontreatment-related deaths from AEs, influenza\/aspergillosis and adenovirus-related hepatitis. Serious AEs (n = 20; 48%) included infections (n = 14) and polyneuropathy (n = 2); treatment-related serious AEs included 2 grade 3 polyneuropathies and 1 grade 3 edema. There were no grade \u2265 3 CNS toxicities or anti-AMG 420 antibodies. In this study, 800 \u03bcg\/d was considered to not be tolerable because of 1 instance each of grade 3 cytokine release syndrome and grade 3 polyneuropathy, both of which resolved. The overall response rate was 31% (n = 13 of 42). At the maximum tolerated dose (MTD) of 400 \u03bcg\/d, the response rate was 70% (n = 7 of 10). Of these, five patients experienced MRD-negative complete responses, and 1 had a partial response, and 1 had a very good partial response; all 7 patients responded during the first cycle, and some responses lasted &gt; 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In this study of AMG 420 in patients with relapsed\/refractory multiple myeloma, the response rate was 70%, including 50% MRD-negative complete responses, at 400 \u03bcg\/d, the MTD for this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.19.02657","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T16:17:41Z","timestamp":1577981861000},"page":"775-783","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":281,"title":["Anti\u2013B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma"],"prefix":"10.1200","volume":"38","author":[{"given":"Max S.","family":"Topp","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Duell","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[{"name":"University of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital Center of Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Langer","sequence":"additional","affiliation":[{"name":"Kempten Clinic, Kempten, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kr\u00f6nke","sequence":"additional","affiliation":[{"name":"Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"Regional University Hospital of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Salnikov","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim, Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lesley","sequence":"additional","affiliation":[{"name":"Amgen, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Beutner","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kalabus","sequence":"additional","affiliation":[{"name":"Amgen, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Riemann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim, Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Minella","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Munzert","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim, Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v32.i4.10"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/7.7.1093"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/22.7.1147"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.11.1693"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116"},{"key":"B12","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.V130.Suppl_1.740.740","volume":"130","author":"Berdeja JG","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116953"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113548"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117729"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110427"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183390"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22237"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647636"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.02657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T04:11:48Z","timestamp":1653797508000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.02657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,3,10]]}},"alternative-id":["10.1200\/JCO.19.02657"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.02657","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"2019-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}